> News

> EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)

News

21/03/2025

EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)

Read the full article below.

Our news

News

02/09/2026
Caelus Receives a Positive EFSA Safety Opinion Under the EU Novel Food Regulation for its Pioneering Gut Bacterium
> READ

News

11/01/2023
Organic S. boulardii: A Probiotic Breakthrough by Lallemand
> READ

News

22/06/2026
Launch of a New CME Course on the Gut Microbiome in Immuno-Oncology
> READ

> See all news